CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma

Zehao Li¹, Xinguang Qiu^{2*}, Qi He², Xinghao Fu², Feihong Ji², Xiufen Tian¹ ¹Department of Pharyngolaryngology Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China ²Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China * Correspondence: Corresponding Author

qxg0914@126.com



Figure S1: A. Smoking status of HNSC patients in the CCND1 amplification group versus HNSC patients in the no-amplification group in the cBioPortal database. B. Alcohol consumption in HNSC patients in the CCND1 amplification group versus HNSC patients in the no-amplification group in the cBioPortal database. C. Cervical lymph node metastasis in HNSC patients in the CCND1 amplification group versus HNSC patients in the no-amplification group in the cBioPortal database.



Figure S2: A. GO enrichment analysis of DEmRNAs. B. KEGG enrichment analysis of DEmRNAs. C. GO enrichment analysis of DEmRNAs for 5 related functions' genes





Figure S3: Expression level of DERNAs in CCND1low expression group and CCND1high expression group. (A) DEIncRNA: C2orf27A, DLEU1. DEmRNA: C11orf24, ERGIC2 (B) DEmRNA: GFPT2, PDPN, RNF4, SOX11. Pairing of gene expression patterns between tumor tissue and normal tissue in patients with HNSC. (C) DEIncRNA: C2orf27A, DLEU1. DEmRNA: C11orf24, ERGIC2 (D) DEmRNA: GFPT2, PDPN, RNF4, SOX11. *p < 0.05, **p < 0.01, ****p < 0.001, ****p < 0.0001. (E) Overall survival: C2orf27A, DLEU1, ERGIC2. (F) Overall survival: GFPT2, PDPN, RNF4. (G) Overall survival: SOX11. (H) Subcellular localization of DLEU1.



Figure S4: A. Expression analysis of has-miR-363-3p in normal tissues and pan-cancer samples. B. Expression analysis of TPRG1-AS1 in normal tissues and pan-cancer samples. C. Expression analysis of MYO1B in normal tissues and pan-cancer samples. *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.001





Figure S5: A. Methylation levels of MYO1B in HNSC. B. Protein expression of MYO1B in HNSC. C. Relationship between methylation sites and expression of MYO1B. D. Distribution of different methylation regions related to MYO1B



Figure S6: The expressions of MYO1B were associated with EMT makers (A) MUC1, (B) CDH2, (C) FN1. Enrichment analysis of MYO1B (D-G)

Description	Gene markers	HNSC-MYO1B	
		correlation	Pvalue
CD8+T cell	CD8A	-0.12319	0.004822
	CD8B	-0.20854	1.54E-06
T cell	CD3D	-0.20293	2.95E-06
	CD3E	-0.13358	0.002225
	CD2	-0.15254	0.00047
B cell	CD19	-0.27796	1.03E-10
	CD79A	-0.27203	2.62E-10
Monocyte	CD86	0.152252	0.000482
	CD115(CSF1R)	0.067013	0.126233
TAM	CCL2	0.041468	0.344364
	CD68	0.164391	0.000162
	IL10	0.17749	4.55E-05
M1 Macrophage	INOS(NOS2)	-0.25476	3.54E-09
	IRF5	-0.19534	6.93E-06
	COX2(PTGS2)	0.207923	1.65E-06
M2 Macrophage	CD163	0.116028	0.007965
	VSIG4	0.07562	0.084339
	MS4A4A	0.054135	0.216913
Neutrophils	CD66b(CEACAM8)	-0.20892	1.47E-06
	CD11b(ITGAM)	-0.08721	0.04642
	CCR7	-0.15346	0.000434
Natural Killer cell	KIR2DL1	-0.01247	0.776283
	KIR2DL3	-0.08083	0.064978
	KIR2DL4	-0.01864	0.67085
	KIR3DL1	-0.14488	0.000901
	KIR3DL2	-0.10606	0.015345
	KIR3DL3	-0.0838	0.055689
	KIR3DS4	-0.06063	0.166625
Dendritic cell	HLA-DPB1	-0.11142	0.010853
	HLA-DQB1	-0.06576	0.133485
	HLA-DRA	-0.02868	0.513213
	HLA-DPA1	-0.03195	0.466375
	BDCA-1(CD1C)	-0.08503	0.052187
	BDCA-4(NRP1)	0.377634	3.88E-19
	CD11c(ITGAX)	-0.01675	0.702671

Gene markers	HNSC-MYO1B	
	correlation	Pvalue
T-bet(TBX21)	-0.15208	0.000489
STAT4	0.141827	0.001158
STAT1	0.337295	2.35E-15
IFN-γ(IFNG)	-0.07691	0.07916
TNF-α(TNF)	0.195449	6.85E-06
GATA3	0.03441	0.432727
STAT6	0.137826	0.001597
STAT5A	-0.10372	0.017766
IL13	-0.05288	0.227744
BCL6	-0.16356	0.000175
IL21	-0.05701	0.193446
STAT3	0.104317	0.017118
IL17A	-0.07912	0.070876
FOXP3	0.038963	0.374319
CCR8	0.150401	0.000565
STAT5B	0.140201	0.001321
TGFβ(TGFB1)	0.513441	1.89E-36
PD-1(PDCD1)	-0.14815	0.000685
CTLA4	-0.03779	0.388933
LAG3	-0.05602	0.201297
TIM-3	0.026495	0.545847
GZMB(HAVCR2)	-0.06728	0.124717
	Gene markers T-bet(TBX21) STAT4 STAT1 IFN-γ(IFNG) TNF-α(TNF) GATA3 STAT6 STAT5A IL13 BCL6 IL21 STAT3 IL17A FOXP3 CCR8 STAT5B TGFβ(TGFB1) PD-1(PDCD1) CTLA4 LAG3 TIM-3 GZMB(HAVCR2)	Gene markers HN correlation T-bet(TBX21) -0.15208 STAT4 0.141827 STAT1 0.337295 IFN-γ(IFNG) -0.07691 TNF-α(TNF) 0.195449 GATA3 0.03441 STAT6 0.137826 STAT5A -0.10372 IL13 -0.05288 BCL6 -0.16356 IL21 -0.05701 STAT3 0.104317 IL17A -0.07912 FOXP3 0.038963 CCR8 0.140201 TGFβ(TGFB1) 0.513441 PD-1(PDCD1) -0.14815 CTLA4 -0.03779 LAG3 -0.05602 TIM-3 0.026495

Table S1: TIMER database query for correlation of MYO1B genes with 16 markers of immune cells infiltrating tumors.

Sequences of gene-specific primers used for real-time RT-qPCR

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
TPRG1-AS1	TCAAAAGGCCTTGATCCCGA	AAGGACTCTGCTTCATGGGTG
MYO1B	GCTCTGGTGTGGAGGTCCTA	CGTTGCTTCCTCAGGTCTTC
miR-363-3p	AATTGCACGGTATCCATCTGTA	CTCAACTGGTGTCGTGGA
GAPDH	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT

Table S2: Sequences of gene-specific primers used for real-time RT-qPCR